Our pancreatic cancer experts can help determine which clinical trial is right for you. Browse our listing of clinical trials that are currently enrolling new patients.

and/or
31 Clinical Trials found
Researchers are finding the best dose of ASP2138 to use in people with advanced digestive cancers. The people in this study have cancer of the pancreas, stomach (gastric cancer), or junction between the esophagus and stomach (gastroesophageal junction cancer). In addition, their cancers make a protein called CLDN 18.2 and keep growing even after treatment.
Researchers want to find the highest dose of ERAS-0015 that can be given safely in people with advanced solid tumors. The people in this study have cancer that has metastasized (spread) and has a mutation in the RAS gene.
Researchers want to find the best dose of INCB161734 to use in people with advanced cancer. The people in this study have solid tumors that have spread. In addition, their cancers have a genetic mutation (change) called KRAS G12D.
Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:
Researchers want to find the best dose of NT-175 in people with advanced solid tumors. The people in this study have cancers that are inoperable (cannot be surgically removed) or metastatic (have spread). The types of tumors include:
BNT326 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called HER3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, BNT326 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Researchers are assessing Lutetium-FAP for people with advanced pancreatic cancer. Lutetium-FAP is a drug with a radioactive part attached. It targets cancer cells that make a protein called FAP, which may help cancer grow and survive. Lutetium-FAP combines a radiation-emitting metal with a tumor-targeting agent to deliver radiation into a tumor and destroy cancer cells.
Researchers are assessing different doses of TNG462 to give with daraxonrasib or zoldonrasib in people with advanced cancer. The people in this study have pancreatic cancer or non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their cancers have a mutation (change) in the RAS gene and are missing a protein called MTAP.
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.